安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Home | Harrow, Inc.
The Investor Relations website contains information about Harrow, Inc 's business for stockholders, potential investors, and financial analysts
- About | Harrow, Inc.
The Investor Relations website contains information about Harrow, Inc 's business for stockholders, potential investors, and financial analysts
- Investor Relations | Harrow, Inc.
The Investor Relations website contains information about Harrow, Inc 's business for stockholders, potential investors, and financial analysts
- News - Harrow, Inc.
The Investor Relations website contains information about Harrow, Inc 's business for stockholders, potential investors, and financial analysts
- Contact | Harrow, Inc.
The Investor Relations website contains information about Harrow, Inc 's business for stockholders, potential investors, and financial analysts
- Harrow to Present at Leerink Partner’s 2026 Global Healthcare . . .
NASHVILLE, Tenn , March 04, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at Leerink Partner’s 2026 Global Healthcare Conference on Tuesday, March 10, 2026, at 8:40 AM ET, in Miami, Florida
- Harrow Launches VEVYE® Access for All
I am so pleased that Harrow is addressing the giant elephant in the room – insurance company tactics that often prevent or delay critical care VEVYE Access for All is a game‑changer, eliminating these barriers, cutting out‑of‑pocket expenses, and empowering physicians to focus on delivering the best possible care
- Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits
PharmaPack Program to Expand Access to Affordable, FDA-Approved Branded Ophthalmic Therapies NASHVILLE, Tenn , Feb 17, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of a new Direct-to-Prescriber (DTP) cash-pay offering called PharmaPack, which expands the Company’s commitment to
|
|
|